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Heart failure (HF) is a chronic heteroge-
neous clinical syndrome that is unified by 
the presence of clinical signs and symptoms 
of congestion and by the difficulty of its diag-
nosis and management. Its prevalence, of 
6.5 million people in the USA,1 is rising due 
to an increasing incidence and to advances in 
medical, interventional and device therapies 
which extend the longevity of the affected 
patients. Despite these advances, HF is char-
acterised by intermittent and recurrent exac-
erbations, which are associated with high 
morbidity, mortality and costs. The estimated 
costs of HF care are 40 billion dollars annually 
in the USA, from which >10 billion are due 
to hospital admissions after presentation to 
an emergency department (ED).2 Currently, 
the care paradigm for patients with HF is 
dichotomous, divided between the care of 
patients with chronic compensated HF in the 
outpatient setting and acute decompensated 
heart failure (ADHF) in an inpatient setting. 
Patients with compensated HF are managed 
longitudinally in outpatient clinics, including 
HF cardiology clinic, general cardiology clinic 
and primary care clinics. Traditionally, each 
of these clinics exist as independent ‘silos’ 
with limited direct communication between 
them. Furthermore, they are designed, 
staffed and supplied to provide traditional 
outpatient care, with limited ability to inter-
vene in a rapid or invasive way. This is clearly 
focused on the evaluation and management 
of compensated patients.
Perhaps it is not surprising that ADHF 
accounts for over 1 million annual ED 
presentations in the USA.2 When a patient 
with ADHF presents to any of the above- 
mentioned clinical offices, there is a limited 
infrastructure and capabilities to address their 
acute needs. For a mild decompensation, 
oral diuretics may be adjusted with a plan for 
follow- up laboratories and phone calls. For 
a more severe decompensation, a patient 
may be directly admitted to the hospital or 
referred to the nearest ED. More than 90% 
of all patients with ADHF presenting to an ED 
are admitted to the hospital, for an average 
length of stay of 5 days.2 Even though inpa-
tient admission for decongestion is the major 
throughput for ADHF care, there have not 
been significant changes in the ED or inpa-
tient care of these patients for the past several 
decades. This is reflected in the most current 
American College of Cardiology/American 
Heart Association (AHA) guidelines from 
2013 and subsequent update in 2017,3 4 which 
do not give guidance for risk stratification of 
ADHF, nor the appropriate care setting of 
therapy. What recommendations are avail-
able primarily focus on in- hospital manage-
ment with decongestion with an intravenous 
diuretic, home HF medical therapy should 
be continued, and for discharge planning. 
Indeed, the high readmission and compli-
cations rates, including death, may be due 
to the lack of clinical trials data and stan-
dardised practices of ADHF management in 
the ED and as inpatients.
We propose that an alternative paradigm 
for the long- term management of patients 
with compensated HF and ones with ADHF 
is needed to improve outcomes of patients 
with HF at lower costs—the 360o HF centre. 
This should be a patient- centred comprehen-
sive, inpatient and outpatient, care model 
that uses a care coordinator to manage 
patients with HF (figure 1). Chronic care 
models using multidisciplinary healthcare 
professionals, such as care coordinators, self- 
care/wellness educators, group therapy/
education, dietitians, clinical pharmacists 
and social workers, have been effective in 
other chronic disease models.5 6 On the 
outpatient side, where the patients with HF 
spend the majority of their time, the model 
must be centred around the patient who will 
be coupled with a care coordinator. A meta- 
analysis of 47 randomised studies of care 
coordination after hospital discharge across 
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Figure 1 360o heart failure centre: a patient- centred comprehensive model for the care for congestive heart failure (HF) . 
The care is centred around the patient with distance of different services representing the frequency and level of support. The 
patient is in the centre of the inner circle and can receive home services, including monitoring and home nursing (capable 
of intravenous (IV) or subcutaneous diuresis (SQ)). The care coordinator, through whom all supportive services provide 
coordinated care, manages all aspect related to the HF management of the patient. Additional services, including dietary, social 
work and pharmacy, have close regular follow- up and interventions with the patient. Other services, including occupational 
health, physical therapy and cardiac rehabilitation, can be used on as- needed basis. Patient continues to follow closely with 
primary care practitioner (PCP) and cardiology clinics (capable of IV or SQ diuresis).
a variety of diagnoses, including HF, showed reduction 
in readmissions, a trend toward reduction in mortality 
and improvement in patient satisfaction.7 Indeed, the 
AHA recommends that care coordination, among other, 
is essential for patients with HF being discharged from 
the hospital after ADHF admission.8 The care coordi-
nator, who may be a mid- level practitioner, like a HF 
nurse practitioner or physician assistant, will be deeply 
familiar with the medical, mental, social and financial 
condition of the patient with HF and be the direct 
point of contact for the patient and other providers 
for any chronic or acute medical status changes. The 
care coordinator must have multidisciplinary support 
staff previously shown to improve clinical outcomes 
for patients with HF including a dietitian,9 10 a clin-
ical pharmacist11 12 and a social worker,13 who can be 
shared with the patient’s primary care physician. Diets, 
like Dietary Approaches to Stop Hypertension and 
the Mediterranean diet, have shown benefits in the 
secondary HF prevention and in reducing the mortality 
in women with HF.9 10 Several randomised controlled 
studies performed in multiple continents found that 
integrating clinical pharmacists in the care of patients 
with HF results in reduction in hospitalisations, either 
from HF or other, which has led to the recommendation 
that clinical pharmacists be part of the team caring for 
patients with HF by the Heart Failure Society of America 
and American College of Clinical Pharmacy Cardiology 
Practice and Research Network.11 12 A major predictor 
for poor outcomes and hospital readmissions for HF 
are inadequate social resources and support,14 which 
can be addressed by a social worker. A randomised trial 
by O’Donnell et al,13 found that a social worker- lead 
palliative care intervention can facilitate end- of- life and 
goals of care discussions in patients with advanced HF. 
Therefore, we propose that these multidisciplinary care 
providers can be strategically used for:
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 ► Dietary education which must take place in the 
patient’s home and while grocery shopping to truly 
be effective in promoting durable lifestyle change.
 ► A clinical pharmacist is instrumental in reviewing 
patients’ medication lists to help evaluate for possible 
deleterious interactions between different medi-
cations not usually prescribed by HF practitioners, 
and suggest alternatives to existing medications, like 
sodium–glucose cotransporter-2 inhibitors in patients 
with diabetes.
 ► A social worker is essential to help the patient and 
provider navigate through the multitude of financial 
and logistical barriers to providing better options for 
medical, mental and financial health.
Additional services such as telehealth and/or 
CardioMEMS should be available to monitor patients 
with HF at home. All patients with HF can benefit from 
daily monitoring for early detection of deviations in 
established haemodynamic parameters. CardioMEMS 
was indicated for high- risk patients, defined as having 
advanced heart failure with New York Heart Association 
III symptoms and a HF hospitalisation in the past year by 
the USA Food and Drug Administration.15 More recently, 
‘real- world’ studies showed more significant reduction 
in pulmonary artery pressures than the initial study and 
significant reduction in HF hospitalisations.16 17 Home 
telehealth monitoring of weight, blood pressure and 
heart rate, which also has been shown to reduce mortality 
in patients with HF,18 19is appropriate for all remaining 
patients. When a patient with HF is identified as having 
a persistent unfavourable change in their monitoring 
parameters by telehealth and/or CardioMEMS, such as 
an increase in weight or pulmonary capillary wedge pres-
sures, they should be contacted to evaluate for correla-
tion with worsening in symptoms.
A 360° HF centre should provide more extensive and 
interventional outpatient services for patients with HF 
than a traditional cardiology clinic. When adjustment of 
oral diuretics is ineffective, elected patients with HF should 
be treated with intravenous or subcutaneous infusions of 
diuretics at home (through home services) or in clinic. 
This, however, requires home and/or clinic services that are 
enabled to administer and monitor the effects of 20 21intra-
venous and/or subcutaneous (for review, see Afari et al22) 
diuretics. In the case of subcutaneous administration, 
patients would need to have their blood drawn (potentially 
before and 1–2 days after administration) to evaluate for 
changes in renal function and electrolytes. With intrave-
nous administration, patients would also need to be moni-
tored for vital sign changes for 3 hours after administration 
and repeated blood draws. The combination of close moni-
toring via telehealth and/or CardioMEMS with the appro-
priate intervention of a care coordinator in HF clinic and 
at home will help with the early management of HF decom-
pensation, thus averting ED presentation and hospital 
admissions usually associated with this patient population.
Patients with ADHF who present to the ED should be 
evaluated by the ‘six- axis model’23 and if determined to 
be low risk could be discharged through close collabora-
tion between the ED and a 360o HF centre. Patients with 
ADHF and high- risk features should be admitted to either 
a medical service with HF specialist consultation or to a 
primary HF service for further management. The inpa-
tient ADHF care should focus on symptomatic improve-
ment of congestion, diuresis to reach euvolaemia and 
evaluation for potential causative factors of the ADHF 
presentation, including cardiac or non- cardiac comor-
bidities, disease progression or dietary/medication non- 
adherence. The 360o HF centre care coordinator and 
multidisciplinary team would be well equipped to create 
an action plan to address such specific HF patient’s 
causative factors and to initiate palliative care consulta-
tion when appropriate. Continuity of care with the care 
coordinator and pharmacist in the 360o HF centre keeps 
consistent messaging regarding dry weight monitoring, 
as well as medication education, key elements in the 
care of patients with HF. Regularly held comprehensive 
discharge planning meetings, incorporating the 360o HF 
centre care team with the inpatient teams, should be held 
to evaluate for need of additional services (such as phys-
ical therapy, ocupational therapy, home health, chore 
worker, telehealth, CardioMEMS or hospice) and to facil-
itate the execution of these multidisciplinary discharge 
plans. At the time of hospital discharge, every patient 
with ADHF must have baseline monitoring parameters 
(including estimated ‘dry weight’), instructions for the 
patient to call the care coordinator for changes in symp-
toms, pharmacy education on medication administration 
and side effects, a 30- day supply of all discharge medica-
tions with prescriptions for refills and a 7- day follow- up 
appointment in the HF clinic. Ultimately, randomised 
clinical trials are needed to assess feasibility, safety and 
effectiveness of inpatient versus outpatient management 
of patients with ADHF presenting to the ED.
There are many barriers to creating an effective 360o 
HF centre. First and most obvious is the belief that the 
costs and reimbursements in the current fee for service 
model will not adequately compensate for the afore-
mentioned services. Diuretic administration through 
subcutaneous or intravenous route have designated 
billable Current Procedural Terminology codes (96365, 
96366, 96374 and 96372) for either push or infusion, 
with similar reimbursement for both the technical and 
the provider fees to many common cardiac procedures, 
like echocardiograms or moderate sedation. As of 2019 
telemedicine now also has billable codes (99 201 and 
99 215 as well as 99452, 99451, 99446, 99447, 99448 and 
99449)24 to account for the services provided to monitor 
and manage patients with HF via home telehealth and/
or CardioMEMS. Second, there are concerns that this 
programme will increase utilisation of medical resources 
and costs. However, it is more likely that by preventing 
costly inpatient admissions, reducing adverse outcomes 
and lost productivity due to ADHF, the costs of a 360o 
HF centre will be more than offset. This must be vali-
dated through clinical studies comparing the costs and 
Library &
. P
rotected by copyright.
 on A
ugust 19, 2020 at W
ashington U
niversity S
chool of M
edicine
http://openheart.bm
j.com
/
O
pen H
eart: first published as 10.1136/openhrt-2019-001221 on 5 July 2020. D
ow
nloaded from
 
Open Heart
4 Halatchev IG, et al. Open Heart 2020;7:e001221. doi:10.1136/openhrt-2019-001221
outcomes of the current standard of care with the 360o 
HF centre, which is in line with the ongoing changes 
to restructure reimbursements based on performance 
metrics rather than the current fee for service model: 
paying for health, not for healthcare.
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